pentobarbital will lessen the extent or impact of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use of alternative treatments is strongly proposed when linagliptin will be to be administered by using a CYP3A4 inducer

pentobarbital will reduce the extent or outcome of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.

fentanyl intranasal and pentobarbital the two maximize sedation. Stay away from or Use Alternate Drug. Limit use to individuals for whom substitute remedy solutions are inadequate

pentobarbital will lower the extent or result of tamoxifen by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital will reduce the extent or effect of elagolix by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.

pentobarbital will lessen the level or outcome of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital will lower the extent or outcome of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will decrease the extent or outcome of sunitinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.

pentobarbital will decrease the extent or impact of cilostazol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital decreases amounts more info of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May perhaps bring about lack of virologic reaction and attainable resistance.

Premature infants are particularly liable to the depressant outcomes of barbiturates; if barbiturates are employed throughout labor and delivery, resuscitation devices must be accessible

pentobarbital will decrease the level or effect of tolterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

Contraindicated (one)pentobarbital will decrease the extent or influence of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is usually a delicate CYP3A4 substrate. Coadministration with sturdy or reasonable CYP3A4 inducers is contraindicated.

pentobarbital will decrease the extent or result of dasatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.